Industry group: Fake APIs a fast-growing problem

European Fine Chemicals Group's Guy Villax said emails promoting fake drugs are the tip of the counterfeiting iceberg. For the past five years, the EFCG has worked to expose what lies below the waterline--falsified APIs. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.